Recent Progress in Radioimmunotherapy for Cancer

ONCOLOGY

Volumn 11, Issue 7, 1997, Pages 979-984

  Meredith, Ruby F ^a   LoBuglio, Albert F ^b   Spencer, Evalina B ^c  

^a The University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; COPPER 67; CYCLOPHOSPHAMIDE; ETOPOSIDE; FERRITIN ANTIBODY; FERRITIN ANTIBODY I 131; INTERLEUKIN 2 RECEPTOR ANTIBODY; IODINE 131; LUTETIUM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49; RADIOISOTOPE; RHENIUM 186; YTTRIUM 90;

ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CARDIOTOXICITY; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRALESIONAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; ISOTOPE LABELING; LIVER TOXICITY; LUNG TOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIATION INJURY; RADIOIMMUNOTHERAPY; SOLID TUMOR; STEM CELL TRANSPLANTATION;

HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 0030845872     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Kohler G, Milstein C: Continuous cultures of fused secreting antibody of redefined specificity. Nature 256:495-497, 1975.
2. Larson SM: Improving the balance between treatment and diagnosis: A role for radioimmunodetection. Cancer Res Suppl 55(23):5756s-5758s, 1995
3. Harrison KA, Tempero MA: Diagnostic use of radiolabeled antibodies for cancer. Oncology 9:625-631, 1995.
4. DeNardo GL, DeNardo SJ: Overview of obstacles and opportunities for radioimmunotherapy of cancer in Goldenberg D (ed): Cancer Therapy With Radiolabeled Antibodies, chap 11, pp 141-154. Boca Raton, Florida, CRC Press, 1995.
5. Wilder RB, DeNardo GL, DeNardo SJ: Radioimmunotherapy: Recent results and future directions. J Clin Oncol 14(4):1383-1400, 1996.
6. Meredith RF, Buchsbaum DJ: Radioimmunotherapy of solid tumors, in Henkin RF, Boles MA, Dillehay GL, et al (eds): Nuclear Medicine, chap 48, pp 601-608. St. Louis, Mosby Year Book, 1996.
7. Buchsbaum DJ: Experimental radioimmunotherapy and methods to increase therapeutic efficacy, in Goldenberg D (ed): Cancer Therapy With Radiolabeled Antibodies, chap 10, pp 115-140. Boca Raton, Florida, CRC Press, 1995.
8. Mausner LF, Srivastava SC: Selection of radionuclides for radioimmunotherapy. Med Phys 20:503-510, 1993.
9. Fritzberg AR, Wessels B: Therapeutic radionuclides, in Wagner HN (ed): Principles of Nuclear Medicine, 2nd ed, section 7, pp 229-234. Philadelphia, WB Saunders, 1995.
10. Dion AS: Humanization of monoclonal antibodies: molecular approaches and applications, in Goldenberg DM (ed): Cancer Therapy With Radiolabeled Antibodies, chap 19, pp 255-270. Boca Raton, Florida, CRC Press, 1995
11. Frankel AE: Immunotoxin therapy of cancer. Oncology 7(5):69-86, 1993.
12. Hozumi N, Sandhu JS. Recombinant antibody technology: Its advent and advances. Cancer Invest 11(6):714-723, 1993.
13. Knox SJ: Radioimmunotherapy of non-Hodgkin's lymphoma. Semin Radiat Oncol 5:331-341, 1995.
14. Jurcic JG, Caron PC, Scheinberg DA: Monoclonal antibody therapy of leukemia and lymphoma. Adv Pharmacol 33:287-314, 1995.
15. Waldmann TA: Lymphokine receptors: A target for immunotherapy of lymphomas. Ann Oncol 5(suppl 1):S13-S17, 1994.
16. Corcoran MC, Press OW, Matthews DC, et al: The role of radioimmunotherapy in bone marrow transplantation. Current Opin Hematol 3:438-445, 1996.
17. Press OW, Eary JF, Appelbaum FR, et al: Treatment of relapsed B cell lymphomas with high-dose radioimmunotherapy and bone marrow transplantation, in Goldenberg DM (ed). Cancer Therapy With Radiolabeled Antibodies, chap 17, pp 229-238. Boca Raton, Florida, CRC Press, 1995.
18. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support- N Engl J Med 329(17):1219-1224, 1993.
19. 131I-Lym-1 and mechanisms for improvement, in Epenetos AA(ed): Monoclonal Antibodies 2, chap 36, pp 355-367. London, Chapman & Hall Medical, 1993.
20. 131I-labeled LL2 (EPB-2) monoclonal antibody. J Clin Oncol 9:548-564, 1991.
21. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14(7):1974-1981, 1996.
22. Czuczman MS, Straus DJ, Divgi CR, et al: Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 11(10):2021-2029, 1993.
23. Vriesendorp HM, Morton JD, Quadri SM: Review of five consecutive studies radiolabeled immunoglobulin therapy in Hodgkin's disease. Cancer Res Suppl 55(23):5888s-5892s, 1995.
24. Bierman PJ, Vose JM, Leichner PK, et al: Yttrium-90 labeled antiferritin followed by high dose chemotherapy and autologous bone marrow transplantation for poor prognosis Hodgkin's disease. J Clin Oncol 11:698-703, 1993.
25. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85:1122-1131, 1995.
26. Meredith RF, Khazaeli MB, Carabasi MH, et al: Radioimmunotherapy of prostate cancer, in Pietro Riva (ed): Therapy of Malignancies With Radioconjugate Monoclonal Antibodies: Present Possibilities and Future Perspectives. Chur, Switzerland, Harwood Academic Publisher, in press.
27. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions Cancer Res Suppl 55(23):5916s-5920s, 1995.
28. 131I conjugated monoclonal antibody CC49: A phase I trial. Antibody Immunconjugates, and Radiopharmaceuticals 6:90, 1993.
29. Murray JL: Radioimmunotherapy of colorectal cancer, in Goldenberg DM (ed): Cancer Therapy With Radiolabeled Antibodies, chap 13, pp 173-188. Boca Raton, Florida, CRC Press, 1995.
30. Paganelli G, Magnani P, Siccardi AG et al: Clinical application of the avidin-biotin system for tumor targeting, in Goldenberg DM (ed): Cancer Therapy With Radiolabeled Antibodies, chap 18, pp 239-254. Boca Raton, Florida, CRC Press, 1995.
31. 131I radio-labeled monoclonal antibodies, in Goldenberg DM (ed): Cancer Therapy With Radiolabeled Antibodies, chap 15, pp 203-216. Boca Raton, Florida, CRC Press, 1995.
32. Maraveyas A, Epenetos AA: Radioimmunotherapy of ovarian cancer, in Goldenberg DM (ed): Cancer Therapy With Radiolabeled Antibodies, chap 12, pp 155-172. Boca Raton, Florida. CRC Press, 1995.
33. Epenetos AA, Munro AJ, Stewart S, et al: Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radio-labeled monoclonal antibodies. J Clin Oncol 5:1890-1899, 1987.
34. Crippa F, Bolis G, Seregni E, et al: Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 1-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 31A(5):686-690, 1995.
35. 90Y with and without EDTA in ovarian cancer. Cancer Invest 10(suppl)38-41, 1992.
36. Jacobs AA, Fer M, Su FM, et al: A phase I trial of rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol 82(4; part 1):586-593, 1993.
37. Meredith R, Alvarez R, Partridge E, et al: Phase I trial of intraperitoneal radioimmunotherapy for ovarian cancer. Im J Radiat Oncol Biol Phys 36(suppl 1):329, 1996.
38. Fein DA, Morgan LS, Marcus RB, et al: Stage III ovarian carcinoma: An analysis of treatment results and complications following hyperfractionated abdomnopelvic irradiation for salvage. Int J Radia Oncol Biol Phys 29:69-176, 1994.
39. Hird V, Maraveyas A, Snook D, et al: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68:403-406, 1993.
40. 131I-labeled anti-tenascin mono- clonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin Cancer Res 2:963-972, 1996
41. Order SE, Siegel JA, Lustig RA, et al: A new method for delivering radioactive cytotoxic agents in solid cancers. Int J Radiat Oncol Biol Phys 30(3)715-720, 1994.
42. Epenetos AA, Courtenay-Luck N, Pickering D, et al: Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen. Br Med J 290:1463-1466, 1985.
43. 125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas. J Neurosurg Sci 34(3-4):243-249, 1990.
44. 125I monoclonal antibody in the management of primary glioblastoma multiforme. Radiat Oncol Invest 3:126-132, 1995.
45. Kemshead JT, Papanastassiou V, Coakham HB, et al: Monoclonal antibodies in the treatment of central nervous system malignancies. Eur J Cancer 28(2/3):511-513, 1992.
46. Pizer BL, Papanastassiou V, Moseley R, et al: Meningeal leukemia and medulloblastoma: Preliminary experience with intrathecal radioimmunotherapy. Antib Immunconj Radiopharmacol 4(4):753-761, 1991.
47. Leichner PK, Akabani G, Colcher D, et al: Patient-specific dosimetry of indium-111-/yttrium-90-labeled monoclonal antibody CC49. J Nucl Med 38(4):512-516, 1997.
48. 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs. Nucl Med Biol 20:571-578, 1993.
49. Dillman RO: Monoclonal antibodies for treating cancer. Ann Intern Med 111:592-603, 1989.
50. Buchsbaum DJ, Raben D, Stackhouse MA, et al: Approaches to enhance cancer radiotherapy employing gene transfer methods. Gene Therapy 3:1042-1068, 1996.